Quantcast

Tourette’s Syndrome Drugs Report, 2019-2023: Market to Witness a CAGR of Approx 5%

DUBLIN–(BUSINESS WIRE)–The “Tourette’s Syndrome Drugs Market by Product and Geography – Global Forecast and Analysis 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The Tourette’s syndrome drugs market analysis considers sales from both antipsychotics and non-antipsychotics products. The analysis also considers the sales of Tourette’s syndrome drugs in Asia, Europe, North America, and RoW.

In 2018, the antipsychotics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the strong therapeutic value of antipsychotics will play a significant role in the antipsychotics segment to maintain its market position.

Also, the global Tourette’s syndrome drugs market report looks at factors such as growing awareness about Tourette’s syndrome, regulatory incentives, and its morbid nature of disease. However, adoption of non-pharmacological therapies, difficulty in diagnosis, and drug in late-stage clinical trials may hamper the growth of the Tourette’s syndrome drugs industry over the forecast period.

Morbid nature of the disease

As Tourette’s syndrome is basically a neurodevelopment syndrome that produces results in repetitive, involuntary movements and unwanted sounds – collectively termed as tics – this syndrome is often accompanied by other disorders such as attention deficit hyperactivity disorder ADHD and obsessive-compulsive disorder OCD. These conditions lead to poor psychological functioning and quality of life. Therefore, a supportive environmental, behavioral and emotional support are necessary to overcome the challenges faced by the patients.

Several non-antipsychotic and atypical antipsychotic drugs, such as quetiapine, olanzapine, risperidone, and aripiprazole are available at low cost that help in suppressing tics in patients with Tourette’s syndrome. This low cost and morbid nature of the disease will lead to the expansion of the global Tourette’s syndrome drugs market at a CAGR of almost 5% during the forecast period.

Development of novel therapeutics

Several pharmaceutical companies and researchers are focusing on the development of novel drugs that correct the dopaminergic disturbances responsible for motor and vocal tics in Tourette’s syndrome patients. For instance, ecopipam, a first-in-class drug developed by Emalex Biosciences, selectively blocks the actions of the neurotransmitter dopamine at the D1 receptor pediatric patients.

Also, Therapix Biosciences is evaluating the efficacy and safety of THX-110, a drug candidate platform for the treatment of symptoms related to Tourette’s syndrome. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global Tourette’s syndrome drugs market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Tourette’s syndrome drugs manufacturers, that include:

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Eli Lilly & Co.
  • H. Lundbeck AS
  • Johnson & Johnson Services Inc.
  • Mylan N.V.
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Also, the Tourette’s syndrome drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • Antipsychotics – Market size and forecast 2018-2023
  • Non-antipsychotics – Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America – Market size and forecast 2018-2023
  • Europe – Market size and forecast 2018-2023
  • Asia – Market size and forecast 2018-2023
  • RoW – Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

  • Development of novel therapeutics
  • Increasing strategic alliances
  • Growing number of research studies to understand genetic root cause of Tourette’s syndrome

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Eli Lilly & Co.
  • H. Lundbeck AS
  • Johnson & Johnson Services Inc.
  • Mylan N.V.
  • Otsuka Holdings Co. Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/2ij6l3

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.